News
3h
Zacks Investment Research on MSNNovartis' Cosentyx Misses Primary Goal in Arteritis Phase III StudyNovartis NVS announced that a late-stage study of its interleukin-17A inhibitor, Cosentyx (secukinumab), has failed to meet ...
Following its acquisition by Supernus Pharmaceuticals, Sage Therapeutics has let go of all of its remaining workforce, which ...
Alphabet-founded biotech Calico Life Sciences has struck an exclusive licensing agreement with Chinese drugmaker Mabwell (SHA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results